Sang is a proven experienced industrial scientist with broad microbiological and molecular biology knowledge in the field of infectious disease research with distinct expertise in synthetic and natural product derived molecules. In his 17 years scientific career as a principal scientist/team leader at Merck and Co., Lodo Therapeutics and currently at Prokaryotics, he possesses significant expertise in leading drug discovery programs from the initial Proof of Concept (POC) stage to more advanced Lead Optimization (LO)stage, including evaluation of lead compounds utilizing various in vivo animal models. Sang received his PhD from Tufts University School of Medicine, in the department of Molecular biology and Microbiology, in the laboratory of Dr. Andrew Camilli, HHMI. He continued his NIH funded post-doctoral fellowship at Yale University in the laboratory of Dr. Jorge Galan studying virulence and pathogenesis of Salmonella bacterial pathogen.
Current role